|
|
|
|
OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
-OctoPlus N.V.('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron,...
|
|
|
OctoPlus appoints Susan Swarte as Chief Financial Officer
- OctoPlus N.V.announced that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of...
|
|
|
OctoPlus appoints Susan Swarte as Chief Financial Officer
- OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the...
|
|
|
OctoPlus appoints Susan Swarte as Chief Financial Officer
OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the...
|
|
|
OctoPlus' Licensee Biolex Therapeutics Completes Patient Enrollment in Phase IIb Study With Locteron
- OctoPlus N.V.('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron...
|
|
|
OctoPlus N.V. (NL) - OctoPlus opens new GMP manufacturing facility
-OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to...
|
|
|
OctoPlus Opens New GMP Manufacturing Facility
- OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to...
|
|
|
OctoPlus Opens New GMP Manufacturing Facility
OctoPlus N.V.('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to...
|
|
|
Study: Ahmed valve survival rate at 63% in patients younger than 2 years
Submit a Comment Patients under the age of 2 years who received an Ahmed valve implantation had a cumulative valve survival rate of more than 60%, with postoperative tube malpositioning the most common postop complication, according to a...
|
|
|
Study: Ahmed valve survival rate at 63% in patients younger than 2 years
Br J Ophthalmol.2009;93(6):795-798. Patients under the age of 2 years who received an Ahmed valve implantation had a cumulative valve survival rate of more than 60%, with postoperative tube malpositioning the most common postop...
|
|
|
OctoPlus N.V. (NL) - OctoPlus to present at two investor conferences in June
-OctoPlus N.V.(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June. Simon Sturge, Chief Executive Officer, will present on...
|
|
|
OctoPlus to Present at Two Investor Conferences in June
- OctoPlus N.V.(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June. Simon Sturge, Chief Executive Officer, will present on...
|
|
|
OctoPlus to present at two investor conferences in June
OctoPlus N.V.(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June. Simon Sturge, Chief Executive Officer, will present on...
|
|
|
OctoPlus to Present at Two Investor Conferences in June
OctoPlus N.V.(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June. Simon Sturge, Chief Executive Officer, will present on...
|
|
|
OctoPlus N.V. (NL) - OctoPlus' licensee Biolex commences Phase IIb study with Locteron
LEIDEN, The Netherlands -- OctoPlus N.V.('OctoPlus' or 'the Company') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on In October 2008 OctoPlus entered into an exclusive license...
|
